The CBR1 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population providing a loss-of-function model for human CBR1 in Raji B lymphoblasts. This product enables study of CBR1 disruption effects without single-cell cloning bias, maintaining population diversity while ensuring gene disruption. Supplied as ready-to-use cells, they are ideal for drug metabolism, cancer biology, and signal transduction research.
The Raji cell line is an EBV-positive human B lymphoblastoid line from a Burkitt’s lymphoma patient. These cells retain B lymphocyte functions including antigen presentation and immunoglobulin production. Widely used in immunology and oncology, Raji cells offer a robust, easy-to-culture platform for gene editing and mechanistic studies.
CBR1 encodes an NADPH-dependent carbonyl reductase that reduces carbonyl substrates including prostaglandins, steroids, and xenobiotics such as doxorubicin and daunorubicin. It catalyzes the conversion of prostaglandin E2 (PGE2) to prostaglandin F2?? (PGF2??), thus influencing FP receptor (PTGFR) signaling. The enzyme also metabolizes anthracyclines to cardiotoxic alcohol metabolites. CBR1 expression is activated by NFE2L2 and AHR in response to oxidative stress and xenobiotics. Within the arachidonic acid metabolism pathway, CBR1 acts downstream of PTGS2 and cooperates with AKR1C3 and HPGD to regulate prostaglandin levels. CBR1 disruption therefore alters PGE2/PGF2?? balance and impairs detoxification of anthracycline chemotherapeutics.
In Raji B lymphoblasts, CBR1 knockout allows dissection of the enzyme??s role in B-cell malignancies, chemoresistance, and redox control. This model is relevant for studying how carbonyl reductase activity affects Burkitt’s lymphoma cell survival, anthracycline-induced cardiotoxicity mechanisms, and immune-related prostaglandin signaling.
Applications include Western blotting, RT-qPCR, enzyme activity assays, and drug sensitivity testing with doxorubicin/daunorubicin. Prostaglandin profiling by LC-MS, apoptosis assays, and RNA-seq enable in-depth mechanistic studies. These cells support research in drug resistance, cardiotoxicity, and cancer biology. For further information, contact Ascent Research.
